Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cabozantinib S-malate (XL184) 是一种多受体酪氨酸激酶抑制剂, 抑制VEGFR2,c-Met,Kit,Axl 和Flt3的IC50分别为0.035,1.3,4.6,7 和 11.3 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 329 | 现货 | ||
10 mg | ¥ 475 | 现货 | ||
25 mg | ¥ 653 | 现货 | ||
50 mg | ¥ 883 | 现货 | ||
100 mg | ¥ 1,310 | 现货 | ||
200 mg | ¥ 2,270 | 现货 | ||
500 mg | ¥ 3,850 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 659 | 现货 |
产品描述 | Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. |
靶点活性 | VEGFR2/KDR:0.035 nM, c-Met:1.3 nM |
体外活性 | Cabozantinib has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] Cabozantinib at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. Cabozantinib also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although Cabozantinib has no significant effect on MPNST cell growth at 0.1 μM, Cabozantinib at 5-10 μM significantly inhibits the MPNST cell growth. [2] |
体内活性 | Cabozantinib treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. Cabozantinib also decreases invasiveness of primary tumors and reduces metastasis. [1] Cabozantinib at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of Cabozantinib induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of Cabozantinib is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3] |
激酶实验 | The inhibition profile of cabozantinib against a broad panel of 270 human kinases is determined using luciferase-coupled chemiluminescence,?33P-phosphoryl transfer, or AlphaScreen technology. Recombinant human full-length, glutathione?S-transferase tag, or histidine tag fusion proteins are used, and half maximal inhibitory concentration (IC50) values are determined by measuring phosphorylation of peptide substrate poly (Glu, Tyr) at ATP concentrations at or below the?Km?for each respective kinase. The mechanism of kinase inhibition is evaluated using the AlphaScreen Assay by determining the IC50?values over a range of ATP concentrations. |
细胞实验 | Cells are exposed to various concentrations of Cabozantinib for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells. (Only for Reference) |
别名 | 苹果酸卡博替尼, Cabozantinib, 卡博替尼苹果酸盐, XL184, Cabozantinib Malate |
分子量 | 635.59 |
分子式 | C32H30FN3O10 |
CAS No. | 1140909-48-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (146.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5733 mL | 7.8667 mL | 15.7334 mL | 39.3335 mL |
5 mM | 0.3147 mL | 1.5733 mL | 3.1467 mL | 7.8667 mL | |
10 mM | 0.1573 mL | 0.7867 mL | 1.5733 mL | 3.9334 mL | |
20 mM | 0.0787 mL | 0.3933 mL | 0.7867 mL | 1.9667 mL | |
50 mM | 0.0315 mL | 0.1573 mL | 0.3147 mL | 0.7867 mL | |
100 mM | 0.0157 mL | 0.0787 mL | 0.1573 mL | 0.3933 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cabozantinib S-malate 1140909-48-3 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors c-Met/HGFR VEGFR TAM Receptor c-Kit 苹果酸卡博替尼 Vascular endothelial growth factor receptor Cabozantinib BMS 907351 Inhibitor XL-184 BMS907351 Cabozantinib S malate 卡博替尼苹果酸盐 Cabozantinib Smalate inhibit XL 184 XL184 Cabozantinib Malate BMS-907351 inhibitor